patisiran ATTR Onpattro
Selected indexed studies
- Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. (N Engl J Med, 2018) [PMID:29972753]
- Delivery Strategies for mRNA Vaccines. (Pharmaceut Med, 2022) [PMID:35094366]
- Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. (Amyloid, 2023) [PMID:35875890]
_Worker-drafted node — pending editorial review._
Connections
patisiran ATTR Onpattro is a side effect of
Sources
- Pathophysiology and Therapeutic Approaches to Cardiac Amyloidosis. (2021) pubmed
- Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. (2018) pubmed
- Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis. (2023) pubmed
- Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. (2023) pubmed
- Disease-modifying therapies for amyloid transthyretin cardiomyopathy: Current and emerging medications. (2025) pubmed
- Delivery Strategies for mRNA Vaccines. (2022) pubmed
- The landscape of nanoparticle-based siRNA delivery and therapeutic development. (2024) pubmed
- Prevalence and clinical outcomes of transthyretin amyloidosis: a systematic review and meta-analysis. (2022) pubmed
- Novel approaches to diagnosis and management of hereditary transthyretin amyloidosis. (2022) pubmed
- Current and emerging treatment options for transthyretin amyloid cardiomyopathy. (2026) pubmed